LEXINGTON, Mass.--(BUSINESS WIRE)--EPIX Pharmaceuticals (NASDAQ: EPIX), today announced compelling top-line results from a Phase 2a two-week clinical trial of its novel 5-HT4 agonist, PRX-03140, in patients with Alzheimer’s disease. The results show that patients receiving 150 mg of PRX-03140 orally once daily as monotherapy achieved a mean 5.7 point improvement on the Alzheimer’s Disease Assessment Scale cognitive subscale (ADAS-cog) versus a 0.2 point worsening in patients on placebo (p= 0.005). Patients on a 50 mg dose of PRX-03140 showed a 1.1 point improvement on the ADAS-cog. The ADAS-cog endpoint is the current standard for evaluating drug efficacy for cognition in Alzheimer’s disease and is an established and accepted registration endpoint.